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Infiltrating CD1a
þ dendritic cells (DCs) have been associated with increased survival in a number of human cancers. This study
investigated DC infiltration within breast cancers and the association with survival. Classical established prognostic factors, of tumour
size, lymph node status, histological grade, lympho-vascular invasion, the KI-67 (MIB-1) fraction and the Nottingham Prognostic Index
(NPI) were also compared. A total of 48 breast cancer patients were followed from the time of surgery and CD1a density analysis for
5 years or until death. Our data set validated previous studies, which show a relationship between survival and the NPI (Po0.001),
tumour size (Po0.01) and lymph node status (Po0.05). Although more patients were alive at the 5-year time point in the group
with higher CD1a DC density than the lower CD1a DC group, this failed to reach statistical significance at the P¼0.05 level. Analysis
at 10 years postsurgery is required to investigate the association further.
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Breast cancer is the most common terminal cancer in women in
developed Western societies (Australian Bureau of Statistics,
2002). The overall survival rate at 5 years is approximately 70%;
however, prognostic factors can define subgroups within the larger
group that may refine this figure to as high as 90% or to less than
20% in individual cases where certain prognostic factors are
known (Pereira et al, 1995; Veronesi et al, 1995). The primary
tumour pathology can predict the extent of local or distant tumour
spread and augment clinical investigational information to better
select appropriate surgery, adjuvant chemotherapy and radio-
therapy and to assist the understanding of likely clinical outcome.
Lymph node involvement, tumour size and the histological grade
of the tumour (Dalton et al, 1994; Page et al, 1998), in order of
prognostic strength of association, are able to predict metastasis,
recurrence and survival (Nixon et al, 1996). These have been
integrated together to form the Nottingham Prognostic Index
(NPI) (Galea et al, 1992). The validity of the NPI has been shown
repeatedly in breast cancer patients over 20 years such that
patients with an NPI of o3.4 have been found to have an overall
15-year survival rate of 80%, those with an NPI of 3.4–5.4 have a
moderate survival rate of 42%, while patients whose NPI is 45.4
have a 15-year survival rate of only 13%. Another feature that has
been associated with clinical outcome is Ki-67 expression
(expressed by all cells not in G0 phase), or the use of the MIB-1
antibody that reacts with part of the Ki-67 antigen (Pinder et al,
1995). Prognostic indices, such as the Nottingham Index, are
important, useful tools that focus on tumour characteristics, but
increasing interest is being directed towards the immunological
responses that occur within the tumour microenvironment
(Austyn, 1993; Coventry, 1999). Studies have shown that activated
lymphocytes can cause tumour-specific cell lysis and that local
immunosuppression appears to be present within the tumour
microenvironment rendering the antitumour immune response
ineffective (Whiteside et al, 1986a,b; Vitolo et al, 1992, 1993;
Coventry et al, 1996, 2002). A possible reason for the poor
antitumour immune response may be the reduced number and
activation status of dendritic cells (DCs) in human breast cancers.
We have previously shown that DCs are absent, or only present in
very low numbers, in most human breast cancers using CD1a and
other markers and that DCs are poorly activated (Coventry et al,
1997; Hillenbrand et al, 1999; Coventry et al, 2002).
CD1a has been reviewed in detail elsewhere (Coventry, 1999);
however in brief, CD1a is a glycosylated type I transmembrane
polypeptide chain noncovalently associated with b2 microglobulin
(Shaw, 1998; Sieling, 1998). There is significant sequence homology
between CD1a, and class I and II molecules of the major
histocompatibility complex (MHC) (Shaw, 1998). The peptide
binding site, while similar to MHC molecules, is longer, deeper and
more hydrophobic (Zeng et al, 1997). CD1a has been used as a
marker for DCs in a range of human tumours and the density of
CD1a DC has been associated with clinical outcome. Dendritic Cell
density, using a variety of markers including CD1a, has been
reported to correlate with survival in a range of human tumour
types including lung (Furukawa et al, 1985; Zeid and Muller, 1993),
colon (Ambe et al, 1989), gastric (Tsujitani et al, 1987),
nasopharyngeal (Gallo et al, 1991a; laryngeal (Gallo et al,
1991b)) and tongue carcinomas (Goldman et al, 1998).
A recent study demonstrated no apparent significant relation-
ship between DC density and survival, using S-100 as a marker for
DC, in formalin-fixed paraffin-embedded breast cancer tissue
samples (Lespagnard et al, 1999). Received 24 December 2002; revised 1 May 2003; accepted 7 May 2003
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yThe aim of this study was to assess the relationship between
CD1a DC density in fresh human breast cancer tissues, with
disease-specific 5-year postsurgery survival. The possible associa-
tion of CD1a density and other established prognostic markers was
also investigated.
METHODS
Patient sample selection
Fresh tissue was taken from 51 female patients following surgical
resection for infiltrating ductal breast carcinoma between 1990 and
1994 at the Royal Adelaide Hospital. Three patients were excluded
due to unavailability of 5-year follow-up data, giving a sample size
of 48. Of these breast carcinomas, 42 tumours were infiltrating
ductal in type and six were ductal carcinomas in situ (DCIS).
Ethical approval was given for the studies by the RAH Human
Ethics Committee.
Tissue processing
Tissue was embedded in OCT (Tissue Tek, Miles Scientific, Illinois)
and snap-frozen in liquid nitrogen. Serial sections (4mm) were cut
using a cryostat (Leica, CM1500, Germany) onto gelatinised slides,
acetone fixed (10min) and air-dried.
Monoclonal antibodies and immunohistochemical
techniques
Mouse anti-human monoclonal antibodies (Mab), diluted with
10% normal horse serum (NHS, Sigma-Aldrich, Sydney) in
phosphate-buffered saline (PBS), were varied in concentration to
determine the optimum dilutions: CD1a at 1:1000 (Dako, Sydney),
Cam 5.2 at 1:500 (Becton Dickinson, Sydney, Australia), murine
isotype controls IgG1, IgG2a (supernatants at 1:16, L Ashman,
IMVS Adelaide, Australia), second antibody biotinylated rabbit
anti-mouse IgG/IgM at 1:500 (Dako, Sydney) and streptavidin–
HRP at 1:1000 (Pierce, USA).
All reactions were carried out with PBS washes in triplicate
between incubations at room temperature. Sections were blocked
with 10% NHS (30min), incubated overnight in a humidified
chamber with primary antibody, followed by biotinylated second
antibody incubation (1h). Endogenous peroxidase blockade (0.5%
hydrogen peroxide; methanol, 20min) was followed by streptavi-
din–HRP incubation (1h). High-sensitivity nickel chloride-
enhanced diaminobenzidene (nickel DAB) techniques were used
and sections were counterstained with methyl green (Coventry
et al, 1994; 1995; Hillenbrand et al, 1999).
Visual quantitation
Cell density was quantified as the mean of 50 random high power
fields (hpf) per frozen section (field size 0.375mm diameter,
0.11mm
2,  400 magnification) using relevant stains for respec-
tive cell types to enable a comparison of the density and
distribution of different cell types (Dunnill, 1968).
Identification of DC
Anti-CD1a Mab was used to identify DC in tissue sections.
Assessment of DC morphology was also performed and assisted
identification.
Identification of tumour cells
The anti-cytokeratin Mab, Cam 5.2, was used to identify tumour
(and normal) epithelial cells in the adenocarcinomas, to exclude
the possibility of CD1a staining of epithelial cells as opposed to DC
(Makin et al, 1984; Hillenbrand et al, 1999).
Follow-up data collection
The 5-year follow-up data were obtained from hospital case notes
and clinical records, general practitioners, surgeons and the
government registry of Deaths. This included interstate follow-
up. The patient details included age at diagnosis/surgery, date of
diagnosis/surgery, duration of follow-up, date of death, cause of
death, date of metastasis/local recurrence and the therapy received.
Pathology data collection
The original pathology reports were obtained for all 48 patients.
These were used to determine the tumour microscopic size, grade,
lymph node status, presence of lympho-vascular invasion and the
Ki-67 (or MIB-1) fraction. The NPI was calculated using this data.
The tumour grade was assessed according to the Scarfe, Bloom and
Richardson system identifying grade I, II or III for each invasive
tumour (Bloom and Richardson, 1957; Scarff and Tolono, 1968).
Ductal carcinoma in situ was also noted separately to any invasive
component, and specifically tabulated if this was the only tumour
present.
Causes of death
For the patients who died, the cause of death was established
through the South Australian Department of Births, Deaths and
Marriages. Breast cancer-specific mortality was used for the
mortality calculations.
Statistics
All statistics were performed with the assistance of statisticians
(see Acknowledgments) using the SAS
r program. The primary
outcome measure was breast cancer-specific survival at 5 years
from the time of diagnosis. Statistical correlations and associations
between survival and the prognostic factors (CD1a density, tumour
size, lymph node status, histological grade, the NPI and the Ki-67
(or MIB-1) fraction) were performed. A correlation between CD1a
density and the NPI was investigated using Fisher’s Exact w
2 test
due to the small sample size used in the study. The prognostic
indicators were treated as categorical, instead of continuous
variables, due also to the small sample size. Indices were used in
standard methodological groupings: the NPI, as recommended by
Galea et al (1992); lymph node metastases into present or absent;
and histological grade was classified as Bloom and Richardson
grades I, II and III or separately as DCIS. CD1a density, tumour
size and Ki-67 fraction were divided into two groups, either side of
the respective medians. The groups were therefore defined around
the medians of: (i) CD1a density 0.78 (cells/hpf), (ii) tumour size
25 (mm) or (iii) Ki-67 fraction 45 (%), respectively. Medians were
chosen on statistical grounds to limit influence from any non-
normal distribution of data. For CD1a density, several cutoff levels
lower and higher than the median were also chosen for extended
analysis.
RESULTS
The data obtained are shown in Table 1. The median age was 60.5
years at diagnosis with a range from 26 to 84 years. Survival data
were obtained for 48 patients with CD1a density (and other)
measurements. Of these, 12 women had died before the 5-year time
point from surgery/diagnosis. All of these deaths were attributable
to breast cancer.
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survival
Tumour size o25mm diameter was demonstrated to be a
prognostic index for survival (Po0.02). The absence of lymph
node metastasis was also found to be associated with survival
(Po0.05). Limited data on nine pathology reports prevented
calculation of the NPI, leaving 39 patients where the NPI was
available. Values ranged from 1.02–7, with 13 women in the good
prognostic group, 20 in the moderate group and six women in the
poor prognostic group. The NPI was strongly associated with
survival (Po0.001), with 100% of women dying in the poor
prognostic group.
The distribution of tumours according to grade was: six DCIS;
eight grade I; 24 grade II and 10 grade III. The histological grade of
the tumour was not significantly associated with survival with a P-
value of 0.08. The Ki-67 (MIB-1) fraction was also not found to be
associated with survival (P¼0.091) in this series. The presence of
lympho-vascular invasion within the tumour was associated with
mortality (P¼0.0126). As expected, the presence of systemic
metastases was associated with reduced survival (Po0.01).
However, in contrast, the presence of local–regional tumour
recurrence was not associated with increased risk of death
(P¼0.304).
CD1a DC density and survival
CD1a staining was confined to DC with no staining of Cam 5.2-
positive epithelial cells in serial sections. The CD1a count was
available for all 48 patients ranging from 0 to 14.85, with a median
of 0.78 cells per high power field. In 40 out of 48 breast cancers,
CD1a-positive cells were detectable using these methods. Compar-
ison of raw data is shown by the dispersion of CD1a density data
around the median for patients alive (Figure 1A) and dead
(Figure 1B) at 5 years postsurgery. A higher death rate (32%) was
observed in the patients with a lower CD1a count, compared to
18% mortality for the group with a higher CD1a density within
their breast tumours. However, the CD1a count was not
significantly associated with 5-year survival (P¼0.331) (Table 2).
The data were also analysed using the Kaplan–Meier method
relating the survival curves of patients with CD1a densities either
less than the median of 0.78cells/hpf or 0.78 and greater (Figure 2).
The association between CD1a count and the NPI was also not
significant (P¼0.486), but again the raw data showed an apparent
trend towards a higher, or a worsening, NPI and lower CD1a
density. The sample (n¼39) for this statistic was necessarily
small due to a lack of complete data for the calculation of the NPI
(Table 3).
Table 1 Patient data for the study group
Median Range
n¼48
Age at diagnosis (years) 60.5 26–84
Age (survivors at 5 years) 67 31–89
Age (died before 5 years) 60.5 41–87
CD1a count (cells/hpf) 0.78 0–14.85
Tumour size (mm) 25 8–200
Nodes removed total 12 1–24
NPI 3.55 1.02–7
Number in category
Tumour grade
DCIS 6
I8
II 24
III 10
DCIS component present 38
Positive nodes 14
Vascular invasion 12
Tamoxifen 21
Radiotherapy 22
Chemotherapy 15
Family history 7
Metastases at diagnosis 2
Metastases at 5 years 10
Ki-67 (+ve 420%) 15
ER (+ve 450%) 24
PR (+ve 450%) 20
16
14
12
10
8
6
4
2
0
C
D
1
a
 
d
e
n
s
i
t
y
 
c
e
l
l
s
/
h
p
f
CD1a density 
Patient
4.50
4.00
3.50
3.00
2.50
2.00
1.50
1.00
0.50
0.00
CD1a density 
C
D
1
a
 
d
e
n
s
i
t
y
 
c
e
l
l
s
/
h
p
f
Patient
B
A
Figure 1 Scattergram showing the dispersion of CD1a density data
around the median (A) for patients alive at 5 years postsurgery and (B) for
patients dead at 5 years postsurgery.
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Figure 2 Survival curves of patients with CD1a densities either less than
the median of 0.78cells/hpf or 0.78 and greater using the Kaplan–Meier
method.
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nodal status, Ki-67 (MIB-1), presence/absence of metastases,
presence/absence of recurrence, presence/absence of lympho-
vascular invasion. No statistical association at the P¼0.05 level
could be found between CD1a density and any of these prognostic
variables.
DISCUSSION
Dendritic cell density in human tumour tissues has been
investigated using a variety of markers and methods. Principally,
CD1a and S-100 have been used for tissue section investigations,
but more recently, CD83, CD86, CMRF-44/-56 and other markers
have been utilised. CD1a molecules have been reviewed elsewhere
(Coventry, 1999), but appear to have a role in antigen presentation
showing relatively tightly restricted expression on DC. A very small
subgroup of monocytes in adults and thymocytes in early life can
also express CD1a. CD1a-positive DCs have been reported to be
present within breast cancers from very early, preinvasive DCIS
lesions to invasive ductal carcinomas, but there was no statistical
correlation between DC density and the grade of the tumour
(Hillenbrand, 1999). On the other hand, S-100-positive DC do
appear to show some correlation with the breast tumour grade
(Bell et al, 1999; Lespagnard et al, 1999), indicating that CD1a and
S-100 define somewhat different populations of DCs in breast
cancers. S-100 is a small acidic regulatory protein involved in a
wide range of cellular processes and exhibits relative tissue
specificity for DCs and cells of neural origin, including melanoma
cells (Heizmann et al, 2002). The density of DCs, using either CD1a
or S-100 as markers for DC, has been reported for a variety of
human cancers including cervix (Younes et al, 1968; Bethwaite
et al, 1996), ovary (Eisenthal et al, 2001), lung (Bassett et al, 1974;
Fox et al, 1989; Zeid and Muller, 1993), larynx (Schenk, 1980),
salivary glands (David and Buchner, 1980), skin (Gatter et al,
1980), breast (Hillenbrand et al, 1999; Coventry et al, 2002),
thymus (Hammar et al, 1986), oesophagus (Matsuda et al, 1990),
stomach (Tsujitani et al, 1987), pancreas (Dallal et al, 2002),
thyroid (Schroder et al, 1988; Willgeroth et al, 1992), colon (Ambe
et al, 1989), nasopharynx (Nomori et al, 1986; Gallo et al, 1991a;
laryngeal (Gallo et al, 1991b)), oral (Kikuchi et al, 2002), prostate,
bladder and kidney (Bigotti et al, 1991; Inoue et al, 1993; Troy et al,
1998a, b, 1999). Furthermore, DC numbers, as measured using
either CD1a or S-100 antibodies, have been positively associated
with improved outcome (increased survival) for many of these
cancers, although the mechanism remains unclear. S-100-positive
DC number has been associated with improved survival for colon,
gastric, lung and laryngeal carcinomas (Tsujitani et al, 1987; Ambe
et al, 1989; Gallo et al, 1991a,b; Zeid and Muller, 1993). More
recently, breast cancer was investigated, but no association of S-
100 with survival could be shown (Lespagnard et al, 1999).
The data regarding CD1a and survival are more limited. The
density of CD1a-positive DC has been directly related to survival
for tongue carcinomas (Goldman et al, 1998) and reduced tumour
recurrence in ovarian carcinoma (Eisenthal et al, 2001). Until
recently, no study has specifically addressed the relationship of
CD1a density in breast cancer to clinical outcome or survival.
Our findings in this study addressed this issue and showed that
the density of tumour infiltrating CD1a
þ dendritic cells did not
significantly correlate (at the P¼0.05 level) with overall survival at
the 5-year time point following surgery. Clearly, sample size may
have been a possible limitation of our study, since a trend was
demonstrated (shown in Table 2). However, the sample size was
sufficiently large to demonstrate a statistical correlation between
the classical prognostic variables of tumour size, lymph node
status, lympho-vascular invasion, metastases and the NPI. Our
data lend further support to the findings of Lespagnard et al (1999)
from a similar study using S-100 as an alternative marker for DC in
formalin-fixed archival breast cancer tissues. Notably, their study
examined 143 cases and also showed no statistical difference
between DC numbers as measured by S-100 expression and 5-year
survival. A very recently published study by Iwamoto et al (2003)
showed similar findings, indicating that CD1a density in breast
cancer was not related to clinical outcome or survival. Taken
collectively, these findings imply that the density of DC per se,a s
measured by CD1a or S-100, does not appear to act as an
independent determinant of overall 5-year survival from breast
carcinoma.
These are important findings and indicate that either (i) DC
density may not directly determine tumour cell growth, metastasis
and outcome in breast cancer or (ii) CD1a and S-100 as
conventional measures of DC density may not be sensitive or
specific enough for prognostic use.
There is considerable evidence that tumour-specific responses
are present in human breast cancers, but that the immune
response is inhibited and/or ineffective in most cases. The
demonstration of tumour-specific lysis by tumour infiltrating
lymphocytes strongly indicates that DCs are important in in vivo
breast cancer antitumour immunity (Baxevanis et al, 1994). The
concept of a detectable antitumour response in breast cancer is
further supported by other demonstrations of tumour-specific
cytolytic and cytokine responses to breast cancer cells utilising
different methods (Whiteside et al, 1986a, b; Shwartzentruber et al,
1992). These findings show that the antitumour immune response
in breast cancer is ineffective and that deficient DC function, at
least in part, may be responsible for this (Coventry et al, 1996;
Gabrilovich et al, 1997). The maturity and location of DC within
breast tumours may not be uniform, such that more mature DCs,
expressing differentiation/activation markers such as CD83, have
been noted to be located peritumourally around the tumour mass,
rather than infiltrating within it (Bell et al, 1999; Tsuge et al, 2000).
Further recent data from two collaborative laboratories, using
different methods and samples, demonstrated that the activation of
DC was very low or absent within the breast cancer microenviron-
ment using a variety of markers (Coventry et al, 2002). The finding
that activation was low or absent in tumour-associated DC
populations in most breast cancers may have some bearing on
the lack of apparent statistical association between CD1a and S-100
expression and survival. The observations that activated, mature
DCs were restricted to a peritumoural location rather than within
the tumour (Bell et al, 1999; Tsuge et al, 2000) imply that regional
Table 2 CD1a density and survival
(n¼47) Dead (%) Alive (%)
Low CD1a 32 68
High CD1a 18 82
Note that 32% of the patients with low CD1a density died within 5 years, while only
18% of those with a count died (n¼47). The association between the number of
CD1a
+ DCs was not significantly associated with survival at 5 years postsurgery
(P¼0.331).
Table 3 Cd1a density and NPI
(n¼39) Low CD1a (%) High CD1a (%)
NPI45.4 (poor prognosis) 80 20
NPI 3.4–5.4 (moderate prognosis) 50 50
NPIo3.4 (good prognosis) 46 54
The association between CD1a and the NPI shows a nonsignificant (P¼0.486)
trend. Note that 20% of the patients with a higher CD1a density had a high
(unfavourable) NPI, while 80% of the patients with a low CD1a density had an
unfavourable NPI. The trend was reversed for a low (more favourable) NPI.
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determining the capacity of DC to present antigens depending on
their location. CD1a
þ DC may not have the capacity to adequately
mature, and present antigen within the tumour microenvironment,
or may become inhibited. Markers of DC differentiation/activa-
tion, such as CD83 and other molecules, may therefore be more
accurate in establishing the true capacity for antigen presentation
within the tumour microenvironment. Clinical evidence for this
theory is provided by recent work that shows that CD83 expression
correlates directly with clinical outcome (Iwamoto et al, 2003). The
presence of a nonstatistically significant trend in the data from
analysis of both (i) CD1a density and survival; and also (ii) CD1a
density and NPI suggests that CD1a
þ DC density may be
important, but this is currently unclear. However, an association
between CD1a expression may reach statistical significance at the
10-year time point from diagnosis, and clearly later analysis is
needed to investigate this aspect. Further studies are necessary to
delineate the role of DC in relation to survival in human breast
cancer, and the mechanisms for enhancing in vivo DC function.
Immunotherapeutic methods for attracting DC into, and activating
DC within, the tumour microenvironment are required to improve
the antitumour immune response. The long dormant periods that
are clinically observed between initial diagnosis/surgery and
subsequent recurrence in the clinical setting strongly indicate that
local mechanisms are operational within the tumour microenvir-
onment and are capable of successfully limiting tumour growth.
Understanding DC function and activation may explain the
mechanism for this phenomenon and reveal new clinically useful
therapeutic tools.
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